In this week’s Innovation Partners BioBlog, we bring you the latest from the world of healthcare. A new head of Health and Human Services was sworn in this week with the Trump Administration promising once again to reduce drug prices. Three global companies joined forces to build their own health
Antibiotic Resistance, Cancer Care in the News
This week’s Innovation Partners BioBlog is focused on the pharmaceutical industry. Attention now turns to the development of new antibiotics to address antimicrobial resistance, as well as to new and improved treatments for various types of cancer. This and more in the BioBlog. Pharmaceutical
Updates and Advances in Cancer Detection
This week’s Innovation Partners BioBlog focuses on advances in cancer detection and screening. A new blood test identifies eight cancer types that account for 60% or more deaths from cancer each year, while a non-invasive blood test may hold promise for colorectal cancer screening. This and more in
Merck, Humana, Teva, and Government Health Regulations in the News
In this week’s Innovation Partners BioBlog, we share updates from companies such as Humana, Merck, and Teva. Humana has chosen to exit industry trade group AHIP, while Teva and Merck announce updates on important new drugs. This and more in this week’s Innovation Partners
Cancer Risks, Treatment, and Drugs in the News
This week’s Innovation Partners BioBlog spotlights cancer risks, treatment, and drugs in the news. A new study out of China that assessed nearly 4 million women working long-term night shifts found an increased risk of cancer. New medications are on the horizon, while the J.P. Morgan Healthcare
Cancer Care and Treatment in the Spotlight This Week
Cancer deaths have dropped to their lowest rate since 1991, mostly in part to fewer Americans smoking. This week’s BioBlog is filled with more good news from the world of oncology and cancer treatment, including advances in the treatment of breast cancer, renal cell carcinoma, squamous cell
A Look at the Top Health News Stories of 2017 and More
2017 was a year of many landmarks, including the highest NMEs approved in any year except 1996. It was a year of many milestones in the war on cancer and a year in which the contentious fight over healthcare, insurance, and who pays for it continued in Congress. A look at these and other top stories